Find a Doctor

Johan F. Vansteenkiste

University Hospital Ku Leuven
Male

Bio


Johan Vansteenkiste is in Leuven, Belgium. He has been an author on 242 peer reviewed articles and participated in 4 clinical trials in the past 15 years.

Contact

Leuven, BE

Latest Advances


Latest Advance
Study
  • Condition: Exon 14-Mutated or Met-Amplified Non-Small Cell Lung Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Capmatinib
  • Number of Patients: 364
  • Published —
This study tested the safety and efficacy of using capmatinib to treat patients with exon 14-mutated or met-amplified non-small cell lung cancer.
Latest Advance
Study
  • Condition: EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Journal: The New England journal of medicine
  • Treatment Used: Osimertinib
  • Number of Patients: 556
  • Published —
This study reported overall survival for osimertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Non-Small Cell Lung Cancer
  • Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • Treatment Used: Ceritinib plus Nivolumab
  • Number of Patients: 36
  • Published —
In this study, researchers evaluated the safety and effectiveness of ceritinib plus nivolumab for the treatment of advanced non-small cell lung cancer.
Latest Advance
Study
  • Condition: Stage IV non-small cell lung cancer
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Necitumumab in combination with abemaciclib
  • Number of Patients: 66
  • Published —
The study researched using Necitumumab in combination with abemaciclib to treat stage IV non-small cell lung cancer.
Latest Advance
Study
  • Condition: Stage III Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Lung cancer (Amsterdam, Netherlands)
  • Treatment Used: Nivolumab added Concurrently to Radiotherapy in a Standard First Line Chemo-Radiotherapy (CRT) Regimen
  • Number of Patients: 82
  • Published —
This study evaluated the safety and effectiveness of nivolumab combined with chemo-radiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).
Latest Advance
Study
  • Condition: Malignant Pleural Mesothelioma
  • Journal: Investigational new drugs
  • Treatment Used: GSK3052230, an FGF Ligand Trap, in Combination with Pemetrexed and Cisplatin
  • Number of Patients: 36
  • Published —
This study evaluated weekly GSK3052230 added to pemetrexed/cisplatin in patients with treatment-naive, unresectable malignant pleural mesothelioma.
Latest Advance
Study
  • Condition: stage III non-small-cell lung cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Durvalumab after chemoradiotherapy
  • Number of Patients: 713
  • Published —
The purpose of the study was to analyze the effectiveness of Durvalumab after chemoradiotherapy for stage III non-small-cell lung cancer.
Latest Advance
Study
  • Condition: Platinum-treated stage IIIB or IV recurrent advanced non-small-cell lung cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Avelumab versus docetaxel
  • Number of Patients: 792
  • Published —
This multi-site phase III study (JAVELIN Lung 200) investigated the efficacy and safety of avelumab compared to docetaxel for patients with stage IIIB or IV recurrent advanced non-small-cell lung cancer previously treated with platinum based chemotherapy. Researchers assessed overall survival.
Latest Advance
Study
  • Condition: Non-small-cell lung cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Durvalumab
  • Number of Patients: 444
  • Published —
This study assessed the effect of durvalumab as third-line or later treatment for advanced non-small-cell lung cancer.

All Publications
View All


Publication
Study
  • Journal: The New England journal of medicine
  • Published —
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Publication
Study
  • Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • Published —
Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

Contact

Leuven, BE

Insurance

Contact them to find out if they accept your insurance plan.